-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Is Now The Time To Put Prestige Consumer Healthcare (NYSE:PBH) On Your Watchlist?
Is Now The Time To Put Prestige Consumer Healthcare (NYSE:PBH) On Your Watchlist?
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story even if these companies are loss-making. But the reality is that when a company loses money each year, for long enough, its investors will usually take their share of those losses. While a well funded company may sustain losses for years, it will need to generate a profit eventually, or else investors will move on and the company will wither away.
In contrast to all that, many investors prefer to focus on companies like Prestige Consumer Healthcare (NYSE:PBH), which has not only revenues, but also profits. Even if this company is fairly valued by the market, investors would agree that generating consistent profits will continue to provide Prestige Consumer Healthcare with the means to add long-term value to shareholders.
See our latest analysis for Prestige Consumer Healthcare
How Fast Is Prestige Consumer Healthcare Growing?
If you believe that markets are even vaguely efficient, then over the long term you'd expect a company's share price to follow its earnings per share (EPS) outcomes. That means EPS growth is considered a real positive by most successful long-term investors. To the delight of shareholders, Prestige Consumer Healthcare has achieved impressive annual EPS growth of 57%, compound, over the last three years. While that sort of growth rate isn't sustainable for long, it certainly catches the eye of prospective investors.
One way to double-check a company's growth is to look at how its revenue, and earnings before interest and tax (EBIT) margins are changing. EBIT margins for Prestige Consumer Healthcare remained fairly unchanged over the last year, however the company should be pleased to report its revenue growth for the period of 11% to US$1.1b. That's encouraging news for the company!
The chart below shows how the company's bottom and top lines have progressed over time. Click on the chart to see the exact numbers.
NYSE:PBH Earnings and Revenue History September 24th 2022You don't drive with your eyes on the rear-view mirror, so you might be more interested in this free report showing analyst forecasts for Prestige Consumer Healthcare's future profits.
Are Prestige Consumer Healthcare Insiders Aligned With All Shareholders?
It's a necessity that company leaders act in the best interest of shareholders and so insider investment always comes as a reassurance to the market. So it is good to see that Prestige Consumer Healthcare insiders have a significant amount of capital invested in the stock. Indeed, they hold US$23m worth of its stock. This considerable investment should help drive long-term value in the business. While their ownership only accounts for 0.9%, this is still a considerable amount at stake to encourage the business to maintain a strategy that will deliver value to shareholders.
It means a lot to see insiders invested in the business, but shareholders may be wondering if remuneration policies are in their best interest. Our quick analysis into CEO remuneration would seem to indicate they are. For companies with market capitalisations between US$2.0b and US$6.4b, like Prestige Consumer Healthcare, the median CEO pay is around US$6.9m.
Prestige Consumer Healthcare's CEO took home a total compensation package worth US$6.0m in the year leading up to March 2022. That comes in below the average for similar sized companies and seems pretty reasonable. While the level of CEO compensation shouldn't be the biggest factor in how the company is viewed, modest remuneration is a positive, because it suggests that the board keeps shareholder interests in mind. It can also be a sign of good governance, more generally.
Should You Add Prestige Consumer Healthcare To Your Watchlist?
Prestige Consumer Healthcare's earnings have taken off in quite an impressive fashion. The sweetener is that insiders have a mountain of stock, and the CEO remuneration is quite reasonable. The strong EPS improvement suggests the businesses is humming along. Big growth can make big winners, so the writing on the wall tells us that Prestige Consumer Healthcare is worth considering carefully. You still need to take note of risks, for example - Prestige Consumer Healthcare has 1 warning sign we think you should be aware of.
There's always the possibility of doing well buying stocks that are not growing earnings and do not have insiders buying shares. But for those who consider these important metrics, we encourage you to check out companies that do have those features. You can access a free list of them here.
Please note the insider transactions discussed in this article refer to reportable transactions in the relevant jurisdiction.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对于许多投资者,尤其是那些缺乏经验的投资者来说,购买有好故事的公司的股票是很常见的,即使这些公司在亏损。但现实是,当一家公司每年亏损时,在足够长的时间内,投资者通常会承担他们的损失份额。虽然一家资金雄厚的公司可能会亏损多年,但它最终需要创造利润,否则投资者就会离开,公司就会枯萎。
与此形成鲜明对比的是,许多投资者更倾向于关注像威望消费者医疗保健(纽约证券交易所股票代码:PBH),它不仅有收入,而且还有利润。即使这家公司得到了市场的公平估值,投资者也会同意,产生持续的利润将继续为Prestige Consumer Healthcare提供为股东增加长期价值的手段。
查看我们对Prestige Consumer Healthcare的最新分析
Prestige Consumer Healthcare的增长速度有多快?
如果你相信市场是模糊有效的,那么从长期来看,你会认为一家公司的股价会跟随其每股收益(EPS)的结果。这意味着,大多数成功的长期投资者认为,每股收益的增长是一个真正的积极因素。令股东高兴的是,Prestige Consumer Healthcare在过去三年中取得了令人印象深刻的57%的年每股收益复合增长率。尽管这种增长速度不会持续很长时间,但它肯定会吸引潜在投资者的目光。
要复核一家公司的增长,一种方法是观察其收入和息税前利润(EBIT)的变化情况。Prestige Consumer Healthcare的EBIT利润率与去年持平,但该公司应高兴地报告其收入增长11%至11亿美元。这对公司来说是个鼓舞人心的消息!
下面的图表显示了该公司的利润和收入是如何随着时间的推移而变化的。点击图表查看确切的数字。
纽约证券交易所:PBH收益和收入历史2022年9月24日你开车的时候眼睛不会盯着后视镜,所以你可能会对这个更感兴趣免费显示分析师对Prestige Consumer Healthcare未来利润。
Prestige Consumer Healthcare内部人员是否与所有股东一致?
公司领导人以股东的最佳利益行事是必要的,因此,内部投资总是对市场起到安抚作用。因此,很高兴看到Prestige Consumer Healthcare内部人士将大量资本投资于该股。事实上,他们持有该公司价值2300万美元的股票。这笔可观的投资应该有助于推动业务的长期价值。虽然他们的持股只占0.9%,但这仍然是一个相当大的风险,以鼓励企业保持将为股东带来价值的战略。
看到内部人士投资于这项业务意义重大,但股东们可能会想,薪酬政策是否符合他们的最佳利益。我们对CEO薪酬的快速分析似乎表明,情况的确如此。对于市值在20亿美元至64亿美元之间的公司,如Prestige Consumer Healthcare,首席执行官的薪酬中值约为690万美元。
在截至2022年3月的一年里,威望消费者医疗保健公司的首席执行官获得了总计600万美元的薪酬方案。这低于类似规模公司的平均水平,似乎相当合理。虽然CEO的薪酬水平不应该是人们如何看待公司的最大因素,但适度的薪酬是一个积极的因素,因为它表明董事会考虑到了股东的利益。更广泛地说,这也可能是良好治理的标志。
您是否应该将Prestige Consumer Healthcare添加到您的观察名单中?
威望消费者医疗保健公司的收益以令人印象深刻的方式增长。更令人欣慰的是,内部人士拥有堆积如山的股票,首席执行官的薪酬相当合理。每股收益的强劲改善表明,企业进展顺利。大增长可以成为大赢家,所以不祥之兆告诉我们,Prestige Consumer Healthcare值得仔细考虑。您仍然需要注意风险,例如-Prestige Consumer Healthcare1个警告标志我们认为你应该意识到。
总是有可能做得很好,购买股票不是不断增长的收入和不要有内部人士购买股票。但对于那些考虑这些重要指标的人,我们建议您查看以下公司做拥有这些功能。你可以在这里访问它们的免费列表。
请注意,本文中讨论的内幕交易指的是相关司法管辖区内的应报告交易。
对这篇文章有什么反馈吗?担心内容吗? 保持联系直接与我们联系。或者,也可以给编辑组发电子邮件,地址是implywallst.com。
本文由Simply Wall St.撰写,具有概括性。我们仅使用不偏不倚的方法提供基于历史数据和分析师预测的评论,我们的文章并不打算作为财务建议。它不构成买卖任何股票的建议,也没有考虑你的目标或你的财务状况。我们的目标是为您带来由基本面数据驱动的长期重点分析。请注意,我们的分析可能不会将最新的对价格敏感的公司公告或定性材料考虑在内。Simply Wall St.对上述任何一只股票都没有持仓。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧